Form 4: PACB CEO Sells Shares for Tax Obligations

Pacific Biosciences CEO Christian O. Henry sold 12,497 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Christian O. Henry, President & CEO of Pacific Biosciences of California, Inc. (PACB), reported a sale of common stock.
• The transaction involved the disposition of 12,497 shares of common stock on March 3, 2026.
• The shares were sold at a weighted average price of $1.514 per share, with prices ranging from $1.49 to $1.56.
• The sale was mandatory, executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Christian O. Henry beneficially owns 3,581,813 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a mandatory, non-discretionary transaction for tax purposes, which is a common practice for executives receiving equity compensation and does not indicate a change in company fundamentals or management sentiment.

Management Comments

• The sale represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units (RSUs) are a common and routine occurrence in the industry. These transactions are typically non-discretionary and do not necessarily reflect a change in management's outlook or confidence in the company's future prospects.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by the CEO to cover tax obligations related to RSU vesting. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the fundamental investment thesis remains unchanged based on this filing.

Keywords

PACB, Pacific Biosciences, Insider Transaction, Form 4, CEO Stock Sale, Tax Withholding, RSU Vesting